通讯作者: 杨颖涛, yangyingtao001@126.com

DOI：10.12201/bmr.202511.00048

Factors Influencing the Efficacy of Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer

• 摘要：目的 探讨人表皮生长因子受体2（Human epidermal growth factor receptor-2, HER2）阴性乳腺癌患者新辅助化疗疗效的影响因素。方法 回顾性收集2020年12月至2024年12月在郑州大学第五附属医院行术前新辅助化疗的79例HER2阴性乳腺癌患者的临床资料，根据术后病理Miller-Payne分级评价其新辅助化疗疗效，采用?2检验分析患者临床病理资料与疗效的关系，二元Logistic回归分析影响疗效的相关因素。结果 将患者分为G1~G3组（n=50例）与G4~G5组（n=29），单因素分析结果显示增殖细胞核抗原Ki-67≥30%、腋窝淋巴结阴性、TNM分期Ⅱ期、三阴型乳腺癌、HER2零表达、病灶无钙化及细胞角蛋白5/6（Cytokeratin 5/6， CK5/6）阳性与更好的新辅助化疗疗效相关。（P值均＜0.05）。多因素分析结果显示，Ki-67≥30%（OR=4.191，P=0.032）、三阴型乳腺癌（OR=6.112，P=0.020）为影响患者新辅助化疗疗效的有利因素，而病灶钙化为独立危险因素（OR=0.243，P=0.041）。结论 Ki-67表达水平、乳腺癌分子分型及病灶有无钙化可作为HER2阴性乳腺癌患者新辅助化疗疗效的有效预测因素。而HER2表达水平不是患者新辅助化疗疗效的独立影响因素。

  关键词： 乳腺癌; HER2阴性; 新辅助化疗; 疗效

   

  Abstract: Objective To investigate the factors influencing the efficacy of neoadjuvant chemotherapy in patients with human epidermal growth factor receptor-2 (HER2)-negative breast cancer. Methods A retrospective analysis was conducted using clinical data from 79 HER2-negative breast cancer who received preoperative neoadjuvant chemotherapy at the Fifth Affiliated Hospital of Zhengzhou University from December 2020 to December 2024. The efficacy of neoadjuvant chemotherapy was evaluated according to the pathological Miller-Payne grading system after surgery. Using the chi-square test to analyze the relationship between the clinicopathological data and their therapeutic efficacy, and binary Logistic regression analysis was used to find the factors influencing therapeutic efficacy. Results Patients were divided into the G1~G3 group (n=50) and the G4~G5 group (n=29). Univariate analysis showed that the marker of proliferation Ki-67 ≥ 30%, negative axillary lymph nodes, TNM stage Ⅱ, triple-negative breast cancer, HER2-negative, no calcification in the lesion and cytokeratin 5/6 (CK5/6) positive were associated with a better therapeutic efficacy of neoadjuvant chemotherapy (all P values were < 0.05). Multivariate analysis showed that Ki-67 ≥ 30% (OR=4.191，P=0.032), triple-negative breast cancer (OR=6.112，P=0.020) were favorable factors influencing the therapeutic efficacy, while calcification in the lesion was an independent risk factor (OR=0.243，P=0.041). Conclusion The Ki-67 expression level, breast cancer molecular subtype, and the presence or absence of calcification in the lesion canbe looked as effective predictive factors for the efficacy of neoadjuvant chemotherapy in patients with HER2-negative breast cancer. While the HER2 expression level is not an independent factor influencing the efficacy of neoadjuvant chemotherapy.

  Key words: breast cancer; HER2-Negative; neoadjuvant chemotherapy; efficacy.

  提交时间：2025-11-19

  版权声明：作者本人独立拥有该论文的版权，预印本系统仅拥有论文的永久保存权利。任何人未经允许不得重复使用。
• html

• 图表

• 阮旭凌, 刘琦, 郭志恒, 晏峻峰. 基于LDA和XGBoost算法的乳腺癌预测模型构建研究. 2022. doi: 10.12201/bmr.202106.00007

  龚悦, 吴欢, 骆玉霜. 循环肿瘤细胞HER-2表达在胃腺癌靶向治疗中的应用. 2024. doi: 10.12201/bmr.202408.00001

  姚根武, 王彦伟, 郭琎祎, 李露露, 党文博, 宋爱琳. 单细胞测序技术在乳腺癌中的研究进展. 2024. doi: 10.12201/bmr.202407.00053

  李莹赟, 袁荷清, 邵喜英. 小分子酪氨酸激酶抑制剂在HER2阳性乳腺癌脑转移治疗研究进展. 2025. doi: 10.12201/bmr.202504.00058

  赵浩森, 曲颜丽. 真实世界中局部晚期胃/胃食管结合部腺癌患者术前化疗的疗效及安全性. 2024. doi: 10.12201/bmr.202409.00052

  林小雷, 马光泛, 陈小珍, 周森. 艾司氯胺酮对乳腺癌患者术后精神状态的影响. 2024. doi: 10.12201/bmr.202412.00054

  邹信哲, 黄婉维, 黄凯君, 江丽君. 乳腺癌患者重返工作现状及影响因素Meta分析. 2025. doi: 10.12201/bmr.202509.00042

  黎秋红, 李全, 朱顺鹏, 邵浩, 周金华. 妊娠合并子宫颈癌多学科诊疗1例报告及文献复习. 2025. doi: 10.12201/bmr.202510.00028

  思小霞, 赵青, 景江新. 超声影像组学在预测乳腺癌分子分型中的应用进展. 2024. doi: 10.12201/bmr.202410.00040

  李苑, 钱琳, 杨义. 中药治疗乳腺癌用药规律研究—基于真实世界的数据挖掘. 2025. doi: 10.12201/bmr.202506.00022

• 序号	提交日期	编号	操作
  1	2025-11-11	10.12201/bmr.202511.00048V1	下载

• 公开评论  匿名评论  仅发给作者 提交评论